Trial Profile
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Aug 2021
Price :
$35
*
At a glance
- Drugs Colesevelam (Primary)
- Indications Gastro-oesophageal reflux
- Focus Registrational; Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 14 Dec 2020 Status changed from recruiting to discontinued.
- 29 Sep 2020 According to an Ironwood Pharmaceuticals media release, based on findings from C3718-302 study, the company plans to discontinue development of IW-3718, including stopping enrollment in this trial.
- 06 Aug 2020 According to an Ironwood Pharmaceuticals media release, if the IDMC determines the data met all pre-specified criteria, Ironwood plans to remain blinded and continue enrollment of the IW-3718-301.